PANEL DISCUSSIONPD 03
PD 03 - AMR
From Market Failure to Tragedy
Date
Sunday, 27th October
Time
11:00-12:30 CEST
10:00-11:30 UTC
Room
Saal 2 - America
Co-Host(s)
About the session
The objective of this session is to review the progress made internationally in combatting Antimicrobial Resistance (AMR) and identify remaining challenges. The session will review the state-of-play of combatting AMR four years after the adoption of the Global Action Plan on AMR and following the report of the Interagency Coordination Group on Antimicrobial Resistance (IACG).
It will present and discuss
• the new international governance for AMR after the finalization of the IACG report,
• how to reinforce the one-health approach and effectively environmental aspects
• new initiatives in fostering the development of new antibacterial treatments and diagnostics
It will present and discuss
• the new international governance for AMR after the finalization of the IACG report,
• how to reinforce the one-health approach and effectively environmental aspects
• new initiatives in fostering the development of new antibacterial treatments and diagnostics
Chair(s) / Moderator(s)
/445x445/dbf8bb4f-2a6b-4ed6-acb0-6057aa24c28b.jpg)
Speakers
/445x445/f1af445d-308f-4d4a-944c-5ac58235f827.jpg)
Robert Koch Institute
President
Germany
Open
/445x445/7029800c-dd33-4b02-aa33-563b82b54a7b.jpg)
Elmar Nimmesgern
Global AMR R&D Hub
Secretariat Lead
Germany
Open
/445x445/87d6e81a-715c-4651-b3e5-1289942428be.jpg)
Felicitas Riedl
European Investment Bank | Life Sciences
Head of Division
Luxembourg
Open
/445x445/b2c0cd29-cb7d-40b9-acac-b012da573050.jpg)
Julia Spencer
MSD Sharp & Dohme GmbH
Associate Vice President, Global Vaccines Public Policy
United States of America
Open